Pulmonary hypertension caused by left heart disease
Conditions
Interventions
Conventional medication group:Guidelines recommend standardized drugs for the treatment of heart failure
combined Qiliqiangxin capsule group:combined Qiliqiangxin capsule
Sponsors
Liaocheng People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age over 18 years old, pulmonary artery systolic pressure >= 40mmHg measured by echocardiography (2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension), clinical diagnosis of heart failure with preserved or reduced ejection fraction (AHA/ACC/HFSA Heart Failure Management Guidelines 2022); 2.Age over 18 years old, pulmonary artery systolic pressure = 40mmHg measured by echocardiography (2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension), clinical diagnosis of heart failure with preserved or reduced ejection fraction (AHA/ACC/HFSA Heart Failure Management Guidelines 2022);
Exclusion criteria
Exclusion criteria: 1.Other types of pulmonary hypertension or targeted drugs for oral lowering of pulmonary arterial hypertension;combined with acute inflammatory response; 2.Concomitant acute inflammatory disease; 3.severe liver and kidney dysfunction; 4.Merge malignant tumors or Immunodeficiency diseases;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary artery systolic pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| HMGB1;CXCL14;6 minutes walk test;NT-proBNP;WHO classification; | — |
Countries
China
Contacts
Public ContactMing-ting Liang
Liaocheng People's Hospital
Outcome results
None listed